MyBCTeam

That's a very specific combination of factors, and it's completely understandable to want clear numbers. The honest answer is that no single survival statistic exists for that exact profile — survival rates are calculated across broader groups, not individual combinations of stage, grade, receptor status, lymph node Show Full Answer

That's a very specific combination of factors, and it's completely understandable to want clear numbers. The honest answer is that no single survival statistic exists for that exact profile — survival rates are calculated across broader groups, not individual combinations of stage, grade, receptor status, lymph node involvement, and Oncotype DX score together.

Here's what is known for ILC that is HR-positive and HER2-negative:

- Early-stage ILC has a five-year survival rate of nearly 100%
- When cancer has spread to nearby tissue or lymph nodes (regional), the five-year survival rate is around 93%
- HR-positive, HER2-negative cancers with low Ki-67 protein levels generally carry a good prognosis An Oncotype DX score of 22 falls in an intermediate range, and treatment decisions around that score can be nuanced. With 3 positive lymph nodes, many oncologists would discuss whether additional treatments beyond radiation — such as hormone therapy — might be beneficial.

This is really a conversation worth having in depth with your oncology team, as they can factor in all of your specific details together to give you the most accurate picture. You deserve answers tailored to *you*, not just general statistics.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Invasive Lobular Breast Cancer: 6 Things To Know